ReviewJournal of cellular and molecular medicine2011
Matrix metalloproteinases: protective roles in cancer.
Review in Journal of cellular and molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Matrix Metalloproteinase-1 Polymorphism,Disease markers · 2018Pooled it
- Lung and blood perioperative metalloproteinases in patients undergoing oncologic lung surgery: Prognostic implications.Thoracic cancer · 2024Trial
- The Dual Role of TGF-β and Hypoxia on MMP14-Mediated Invasion in PC3 Cells.Cell biochemistry and biophysics · 2026Article
- Review
- Serum TIMP-1 concentrations are associated with cancer incidence and cancer-related mortality in a population-based cohort.Scientific reports · 2026Article
- Integrated Single-Cell and Spatial Profiling of MMP Gene Expression in Colorectal Cancer.bioRxiv : the preprint server for biology · 2026Article
- Opposing prognostic roles of tumor-associated and circulating MMP8 in colorectal cancer.Clinical and experimental medicine · 2026Article
- Gene Expression Alterations Associated With Resveratrol-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Osteosarcoma Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer.Scientific reports · 2026Article
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential.Frontiers in oncology · 2026Article
- Evaluating the CRP Interactome: Insights into Possible Novel Roles in Cellular Signaling and Tumorigenicity.Current issues in molecular biology · 2025Review
- Identification of Salivary Biomarkers in Colorectal Cancer by Integrating Olink Proteomics and Metabolomics.Journal of proteome research · 2025Article
- Potential target within the tumor microenvironment - MT1-MMP.Frontiers in immunology · 2025Review
- Dual roles of myeloid-derived suppressor cells in various diseases: a review.Archives of pharmacal research · 2024Review
- The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects.Cell death & disease · 2024Article
- MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-AP1-MMPs axis.Scientific reports · 2024Article
- Deciphering the role of wound healing genes in skin cutaneous melanoma: Insights into expression, methylation, mutations, and therapeutic implications.International wound journal · 2024Article
- Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC).Oncology research · 2024Article
- Computational design of matrix metalloprotenaise-9 (MMP-9) resistant to auto-cleavage.The Biochemical journal · 2023Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The original notion that matrix metalloproteinases (MMPs) act as tumour and metastasis-promoting enzymes by clearing a path for tumour cells to invade and metastasize has been challenged in the last decade. It has become clear that MMPs are involved in numerous steps of tumour progression and metastasis, and hence are now considered to be multifaceted proteases. Moreover, more recent experimental evidence indicates that some members of the MMP family behave as tumour-suppressor enzymes and should therefore be regarded as anti-targets in cancer therapy. The complexity of the pro- and anti-tumorigenic and -metastatic functions might partly explain why broad-spectrum MMP inhibitors failed in phase III clinical trials. This review will provide a focussed overview of the published data on the tumour-suppressive behaviour of MMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.